MCM
TLX

MV Capital Management’s Telix Pharmaceuticals TLX Stock Holding History

MV Capital Management’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$584 Buy
61
+50
+455% +$381 ﹤0.01% 948
2025
Q4 		$83 Buy
+11
New +$106 ﹤0.01% 1123

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $312M AUM 53.32% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $6.97B AUM 29.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

MV Capital Management's TLX Position: Q1 2026 in Review

MV Capital Management increased its Telix Pharmaceuticals (TLX) stake by 455% in Q1 2026, buying an estimated $381 and bringing the position to 61 shares worth $584. The position accounts for ﹤0.01% of the portfolio, ranked #948.

MV Capital Management first reported a position in TLX in Q4 2025 and has held it in 2 quarters since. 39 funds tracked by Wall St. Rank hold TLX as of Q1 2026.

  • MV Capital Management held 61 shares of Telix Pharmaceuticals worth $584 as of Q1 2026.
  • MV Capital Management bought 50 Telix Pharmaceuticals shares in Q1 2026, an estimated $381.
  • Telix Pharmaceuticals made up ﹤0.01% of MV Capital Management's portfolio in Q1 2026, its #948 holding.
  • MV Capital Management first reported a position in Telix Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 39 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q1 2026.

Based on MV Capital Management's 13F filing for Q1 2026, filed 30 Apr 2026.